Author:
Wang Ni,Yang Ying,Xu Luxinyi,Mao Zongfu,Cui Dan
Abstract
Abstract
Background
The Chinese government implemented the first round of National Centralized Drug Procurement (NCDP) pilot (so-called “4 + 7” policy) in mainland China in 2019. This study aims to examine the impact of “4 + 7” policy on the price of policy-related drugs.
Methods
This study used drug purchasing order data from the Centralized Drug Procurement Survey in Shenzhen 2019, covering 24 months from January 2018 to December 2019. “4 + 7” policy-related drugs were selected as study samples, including 25 drugs in the “4 + 7” procurement list and 57 alternative drugs that have an alternative relationship with “4 + 7” List drugs in clinical use. “4 + 7” List drugs were then divided into bid-winning and bid-non-winning products according to the bidding results. Single-group Interruption Time Series (ITS) analysis was adopted to examine the change of Drug Price Index (DPI) for policy-related drugs.
Results
The ITS analysis showed that the DPI of winning (− 0.183 per month, p < 0.0001) and non-winning (− 0.034 per month, p = 0.046) products significantly decreased after the implementation of “4 + 7” policy. No significant difference was found for the immediate change of DPI for alternative drugs (p = 0.537), while a significant decrease in change trend was detected in the post-“4 + 7” policy period (− 0.003 per month, p = 0.014). The DPI of the overall policy-related drugs significantly decreased (− 0.261 per month, p < 0.0001) after “4 + 7” policy.
Conclusions
These findings indicate that the price behavior of pharmaceutical enterprises changed under NCDP policy, while the price linkage effect is still limited. It is necessary to further expand the scope of centralized purchased drugs and strengthen the monitoring of related drugs regarding price change and consumption structure.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference34 articles.
1. Parkinson B, Sermet C, Clement F, Crausaz S, Godman B, Garner S, et al. Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review. Pharmacoeconomics. 2015;33(9):905–24. https://doi.org/10.1007/s40273-015-0293-8.
2. Smith C. Retail prescription drug spending in the national health accounts. Health Aff. 2004;23(1):160–7. https://doi.org/10.1377/hlthaff.23.1.160.
3. The IQVIA Institute. Global medicine spending and usage trends outlook to 2024. 2020. https://www.iqvia.com/insights/the-iqvia-institute/reports/global-medicine-spending-and-usage-trends. Accessed 11 Jan 2021.
4. The Central People’s Government of the People’s Republic of China. 2019 statistical bulletin of China’s health development. 2020. http://www.gov.cn/guoqing/2021-04/09/content_5598657.htm. Accessed 25 Apr 2021.
5. Zhai T, Zhang Y, Wan Q, Chai P, Guo F, Li Y, et al. The results and analysis of national health accounts in China in 2018. Chin Health Econ. 2020;39(6):5–8. https://doi.org/10.7664/CHE20200601.
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献